WHO ruling could put fate of world’s first dengue vaccine on the line

There’s a lot on the line this week for Sanofi Pasteur’s troubled dengue vaccine, Dengvaxia.

On Wednesday, an expert panel that advises the World Health Organization will vote to update its recommendations outlining how and when the vaccine should be used — and, more importantly, how and when it should not be administered. A decision is expected Thursday.

Dengvaxia is the first licensed vaccine that protects against dengue. Data generated by Sanofi shows that while the vaccine is protective for people who have previously been infected with dengue, it actually increases the risk of severe disease for people who are vaccinated when they are dengue naïve — never before infected.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In